Cohort characteristics
| . | PT-CY Haplo, n (%) . | 10/10 MUD, n (%) . | Total . | P value . |
|---|---|---|---|---|
| No. of patients | 487 | 7050 | 7537 | |
| Patient age, y | <.001 | |||
| 18-19 | 10 (2.1) | 73 (1) | 83 | |
| 20-29 | 48 (9.9) | 385 (5.5) | 433 | |
| 30-39 | 36 (7.4) | 457 (6.5) | 493 | |
| 40-49 | 72 (14.8) | 1053 (14.9) | 1125 | |
| 50-59 | 126 (25.9) | 2088 (29.6) | 2214 | |
| 60-69 | 166 (34.1) | 2394 (34) | 2560 | |
| 70-79 | 29 (6) | 600 (8.5) | 629 | |
| Diagnosis | ||||
| AML | 233 (47.8) | 2926 (41.5) | 3159 | <.001 |
| MDS/MPN | 74 (15.2) | 1710 (24.3) | 1784 | |
| NHL | 65 (13.3) | 640 (9.1) | 705 | |
| ALL | 57 (11.7) | 575 (8.2) | 632 | |
| MM | 19 (3.9) | 432 (6.1) | 451 | |
| SecAL | 17 (3.5) | 319 (4.5) | 336 | |
| CLL | 2 (0.4) | 165 (2.3) | 167 | |
| CML | 7 (1.4) | 149 (2.1) | 156 | |
| AL | 5 (1) | 89 (1.3) | 94 | |
| HL | 8 (1.6) | 45 (0.6) | 53 | |
| Disease stage | ||||
| Early | 218 (44.8) | 3119 (44.2) | 3337 | .956 |
| Intermediate | 100 (20.5) | 1473 (20.9) | 1573 | |
| Advanced | 167 (34.3) | 2438 (34.6) | 2605 | |
| Missing | 2 (0.4) | 20 (0.3) | 22 | |
| KPS | ||||
| ≥80 | 434 (89.1) | 6178 (87.6) | 6612 | .011 |
| <80 | 36 (7.4) | 407 (5.8) | 443 | |
| Missing | 17 (3.5) | 465 (6.6) | 482 | |
| Source | ||||
| PBSC | 365 (74.9) | 6791 (96.3) | 7156 | <.001 |
| BM | 119 (24.4) | 238 (3.4) | 357 | |
| Missing | 3 (0.6) | 21 (0.3) | 24 | |
| Previous auto-HSCT | ||||
| Yes | 63 (12.9) | 829 (11.8) | 892 | .481 |
| No | 424 (87.1) | 6221 (88.2) | 6645 | |
| Conditioning intensity | ||||
| MAC | 290 (59.5) | 3711 (52.6) | 4001 | .003 |
| RIC | 197 (40.5) | 3339 (47.4) | 3536 | |
| Immunosuppression | ||||
| CNI + MMF | 436 (89.5) | 3623 (51.4) | 627 | <.001 |
| CNI + MTX | 1 (0.2) | 2530 (35.9) | 4057 | |
| CNI | 17 (3.5) | 610 (8.7) | 2531 | |
| Other | 33 (6.8) | 287 (4.1) | 320 | |
| Year of HSCT | ||||
| 2010-2015 | 68 (14) | 3844 (54.5) | 3912 | <.001 |
| 2016-2020 | 419 (86) | 3206 (45.5) | 3625 | |
| Sex mismatch | ||||
| Yes | 109 (22.4) | 649 (9.2) | 758 | <.001 |
| No | 376 (77.2) | 6066 (86) | 6442 | |
| Missing | 2 (0.4) | 335 (4.8) | 337 | |
| Donor age, y | ||||
| 0-19 | 26 (5.3) | 164 (2.3) | 190 | <.001 |
| 20-29 | 110 (22.6) | 1753 (24.9) | 1863 | |
| 30-39 | 149 (30.6) | 1182 (16.8) | 1331 | |
| 40-49 | 106 (21.8) | 617 (8.8) | 723 | |
| 50-59 | 56 (11.5) | 208 (3) | 264 | |
| 60-99 | 16 (3.3) | 12 (0.2) | 28 | |
| Missing | 24 (4.9) | 3114 (44.2) | 3138 | |
| HCT-CI score | ||||
| 0 | 208 (42.7) | 1908 (27.1) | 2116 | <.001 |
| ≥1 | 267 (54.8) | 2817 (40) | 3084 | |
| Missing | 12 (2.5) | 2325 (33) | 2337 | |
| CMV Pat. Don. | ||||
| Neg. neg. | 122 (25.1) | 2455 (34.8) | 2577 | <.001 |
| Neg. pos. | 42 (8.6) | 571 (8.1) | 613 | |
| Pos. neg. | 92 (18.9) | 1294 (18.4) | 1386 | |
| Pos. pos. | 228 (46.8) | 2614 (37.1) | 2842 | |
| Missing | 3 (0.6) | 116 (1.6) | 119 | |
| TBI | ||||
| Yes | 111 (22.8) | 1634 (23.2) | 1745 | <.001 |
| No | 373 (76.6) | 5412 (76.8) | 5785 | |
| Missing | 3 (0.6) | 4 (0.1) | 7 |
| . | PT-CY Haplo, n (%) . | 10/10 MUD, n (%) . | Total . | P value . |
|---|---|---|---|---|
| No. of patients | 487 | 7050 | 7537 | |
| Patient age, y | <.001 | |||
| 18-19 | 10 (2.1) | 73 (1) | 83 | |
| 20-29 | 48 (9.9) | 385 (5.5) | 433 | |
| 30-39 | 36 (7.4) | 457 (6.5) | 493 | |
| 40-49 | 72 (14.8) | 1053 (14.9) | 1125 | |
| 50-59 | 126 (25.9) | 2088 (29.6) | 2214 | |
| 60-69 | 166 (34.1) | 2394 (34) | 2560 | |
| 70-79 | 29 (6) | 600 (8.5) | 629 | |
| Diagnosis | ||||
| AML | 233 (47.8) | 2926 (41.5) | 3159 | <.001 |
| MDS/MPN | 74 (15.2) | 1710 (24.3) | 1784 | |
| NHL | 65 (13.3) | 640 (9.1) | 705 | |
| ALL | 57 (11.7) | 575 (8.2) | 632 | |
| MM | 19 (3.9) | 432 (6.1) | 451 | |
| SecAL | 17 (3.5) | 319 (4.5) | 336 | |
| CLL | 2 (0.4) | 165 (2.3) | 167 | |
| CML | 7 (1.4) | 149 (2.1) | 156 | |
| AL | 5 (1) | 89 (1.3) | 94 | |
| HL | 8 (1.6) | 45 (0.6) | 53 | |
| Disease stage | ||||
| Early | 218 (44.8) | 3119 (44.2) | 3337 | .956 |
| Intermediate | 100 (20.5) | 1473 (20.9) | 1573 | |
| Advanced | 167 (34.3) | 2438 (34.6) | 2605 | |
| Missing | 2 (0.4) | 20 (0.3) | 22 | |
| KPS | ||||
| ≥80 | 434 (89.1) | 6178 (87.6) | 6612 | .011 |
| <80 | 36 (7.4) | 407 (5.8) | 443 | |
| Missing | 17 (3.5) | 465 (6.6) | 482 | |
| Source | ||||
| PBSC | 365 (74.9) | 6791 (96.3) | 7156 | <.001 |
| BM | 119 (24.4) | 238 (3.4) | 357 | |
| Missing | 3 (0.6) | 21 (0.3) | 24 | |
| Previous auto-HSCT | ||||
| Yes | 63 (12.9) | 829 (11.8) | 892 | .481 |
| No | 424 (87.1) | 6221 (88.2) | 6645 | |
| Conditioning intensity | ||||
| MAC | 290 (59.5) | 3711 (52.6) | 4001 | .003 |
| RIC | 197 (40.5) | 3339 (47.4) | 3536 | |
| Immunosuppression | ||||
| CNI + MMF | 436 (89.5) | 3623 (51.4) | 627 | <.001 |
| CNI + MTX | 1 (0.2) | 2530 (35.9) | 4057 | |
| CNI | 17 (3.5) | 610 (8.7) | 2531 | |
| Other | 33 (6.8) | 287 (4.1) | 320 | |
| Year of HSCT | ||||
| 2010-2015 | 68 (14) | 3844 (54.5) | 3912 | <.001 |
| 2016-2020 | 419 (86) | 3206 (45.5) | 3625 | |
| Sex mismatch | ||||
| Yes | 109 (22.4) | 649 (9.2) | 758 | <.001 |
| No | 376 (77.2) | 6066 (86) | 6442 | |
| Missing | 2 (0.4) | 335 (4.8) | 337 | |
| Donor age, y | ||||
| 0-19 | 26 (5.3) | 164 (2.3) | 190 | <.001 |
| 20-29 | 110 (22.6) | 1753 (24.9) | 1863 | |
| 30-39 | 149 (30.6) | 1182 (16.8) | 1331 | |
| 40-49 | 106 (21.8) | 617 (8.8) | 723 | |
| 50-59 | 56 (11.5) | 208 (3) | 264 | |
| 60-99 | 16 (3.3) | 12 (0.2) | 28 | |
| Missing | 24 (4.9) | 3114 (44.2) | 3138 | |
| HCT-CI score | ||||
| 0 | 208 (42.7) | 1908 (27.1) | 2116 | <.001 |
| ≥1 | 267 (54.8) | 2817 (40) | 3084 | |
| Missing | 12 (2.5) | 2325 (33) | 2337 | |
| CMV Pat. Don. | ||||
| Neg. neg. | 122 (25.1) | 2455 (34.8) | 2577 | <.001 |
| Neg. pos. | 42 (8.6) | 571 (8.1) | 613 | |
| Pos. neg. | 92 (18.9) | 1294 (18.4) | 1386 | |
| Pos. pos. | 228 (46.8) | 2614 (37.1) | 2842 | |
| Missing | 3 (0.6) | 116 (1.6) | 119 | |
| TBI | ||||
| Yes | 111 (22.8) | 1634 (23.2) | 1745 | <.001 |
| No | 373 (76.6) | 5412 (76.8) | 5785 | |
| Missing | 3 (0.6) | 4 (0.1) | 7 |
AL, acute leukemia; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; auto-HSCT, autologous haematopoietic stemm cell transplantation; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; CMV Pat. Don., cytomegalovirus serostatus patient and donor; CNI, calcineurin inhibitors; HCT-CI, haemopoietic cell transplantation-spesific comorbidity index; MDS/MPN, myelodysplastic syndrome/myeloproliferative neoplasm; MM, multiple myeloma; MMF, mycophenolate mofetil; MTX, methotrexate; neg., negative; NHL, non hodgkin`s lymphoma; pos., positive; TBI, total body irradiation.